MOLOGEN AG
MOLOGEN AG: Results of the exploratory phase II study in extensive-disease small-cell lung cancer (SCLC)
MOLOGEN AG / Key word(s): Study results Insider information according to article 17 MAR MOLOGEN AG: Results of the exploratory phase II study in extensive-disease small-cell lung cancer (SCLC) IMPULSE showed positive results in two pre-defined and clinically relevant subgroups of patients. Notably, a strong overall survival (OS) benefit was shown in comparison to the control arm (local standard of care) in patients with a low count of activated B cells, an important immune parameter. Moreover, a benefit was seen in patients with reported Chronic Obstructive Pulmonary Disease (COPD), a frequent underlying disease. Additional, potentially promising subgroups will be explored. The results of this SCLC-study provide significant guidance for defining patient populations most likely to benefit from lefitolimod, even though in this highly challenging indication the primary endpoint OS was not met in the overall study population. A more extensive evaluation of the IMPULSE data is currently ongoing, and further results will be presented at international scientific congresses. These study results will be an important asset in the ongoing partnering discussions. Further to the IMPULSE study, lefitolimod is currently being evaluated in the indications metastatic colorectal cancer, other solid tumors, and in HIV. Contact Note about risk for future predictions
22-Apr-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | MOLOGEN AG |
Fabeckstraße 30 | |
14195 Berlin | |
Germany | |
Phone: | 030 / 841788-0 |
Fax: | 030 / 841788-50 |
E-mail: | presse@mologen.com |
Internet: | www.mologen.com |
ISIN: | DE0006637200 |
WKN: | 663720 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
End of Announcement | DGAP News Service |